NovaGold Resources Inc. (USA) (NG) Reaches $4.69 After 5.00% Down Move, Affimed NV (AFMD) Sellers Increased By 7.21% Their Shorts

June 28, 2017 - By Migdalia James

Affimed NV (NASDAQ:AFMD) had an increase of 7.21% in short interest. AFMD’s SI was 886,200 shares in June as released by FINRA. Its up 7.21% from 826,600 shares previously. With 201,000 avg volume, 4 days are for Affimed NV (NASDAQ:AFMD)’s short sellers to cover AFMD’s short positions. The SI to Affimed NV’s float is 3.19%. About 87,677 shares traded. Affimed NV (NASDAQ:AFMD) has declined 19.09% since June 28, 2016 and is downtrending. It has underperformed by 35.79% the S&P500.

The stock of NovaGold Resources Inc. (USA) (NYSEMKT:NG) is a huge mover today! About 933,135 shares traded. NovaGold Resources Inc. (USA) (NYSEMKT:NG) has declined 29.36% since June 28, 2016 and is downtrending. It has underperformed by 46.06% the S&P500.The move comes after 9 months negative chart setup for the $1.58 billion company. It was reported on Jun, 28 by Barchart.com. We have $4.46 PT which if reached, will make NYSEMKT:NG worth $79.00M less.

Novagold Resources Inc. is a mineral exploration company. The company has market cap of $1.58 billion. The Firm is engaged in the exploration and development of mineral properties. It currently has negative earnings. The Company’s divisions include the Donlin Gold project in Alaska, the United States and the Galore Creek project in British Columbia, Canada.

Affimed N.V. is a clinical-stage biopharmaceutical firm focused on discovering and developing cancer immunotherapies. The company has market cap of $92.13 million. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. It currently has negative earnings. The Company’s pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs.

Among 7 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 4 have Buy rating, 0 Sell and 3 Hold. Therefore 57% are positive. Affimed Therapeutics had 13 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Sell” rating by Zacks given on Monday, August 10. Leerink Swann downgraded the stock to “Market Perform” rating in Friday, August 12 report. The stock has “Outperform” rating by Oppenheimer on Thursday, August 6. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Outperform”. BMO Capital Markets initiated the shares of AFMD in report on Tuesday, April 12 with “Outperform” rating. The firm earned “Market Perform” rating on Thursday, May 19 by Leerink Swann. On Thursday, May 19 the stock rating was maintained by Jefferies with “Hold”. On Thursday, September 3 the stock rating was upgraded by Zacks to “Hold”. The stock has “Hold” rating by Jefferies on Wednesday, September 9. On Thursday, December 10 the stock rating was initiated by Laidlaw with “Buy”.